Core Points - The company approved the use of up to RMB 300 million of idle raised funds for cash management, valid for 12 months from the board's approval date [1] - The company has redeemed principal and investment income from previously purchased capital-protected products, returning the funds to the designated account [1]

Group 1 - The company has approved the use of idle raised funds for cash management, with a limit of up to RMB 265 million [2] - The cash management plan was approved during meetings held on August 29, 2024, and September 19, 2024, ensuring the safety and normal operation of the raised funds [2] - The cash management period is valid for 12 months from the date of approval by the shareholders' meeting [2] Group 2 - As of August 22, 2025, the company has fully redeemed all idle raised funds used for cash management and returned them to the designated account [3] - The company has informed the sponsor institution, Huatai United Securities, about the redemption of the raised funds [3] - The cash management activities were conducted within the approved amount and timeframe, with all financial products maturing and redeemed as planned [3]

Core Viewpoint - Shenzhen Zhishang Technology Co., Ltd. has approved the use of idle raised funds (including oversubscribed funds) for cash management to enhance fund utilization efficiency and increase cash asset returns, with a limit of up to RMB 1 billion for a period of twelve months [1][6]. Group 1: Cash Management Approval - The company held board and supervisory meetings on April 17, 2025, and a shareholder meeting on May 9, 2025, to approve the cash management proposal [1][2]. - Independent directors and the sponsor institution expressed clear agreement on the cash management plan [2]. Group 2: Cash Management Implementation - The company has redeemed cash management products purchased with idle raised funds and will continue cash management activities [3]. - The total unused balance of idle raised funds for cash management as of the announcement date is RMB 895 million, which is within the approved limit of RMB 1 billion [7]. Group 3: Risk Control Measures - The company will invest only in high-security, liquid financial products with a maturity of no more than 12 months, primarily influenced by macroeconomic policies [3][4]. - Strict adherence to regulatory guidelines and internal management systems will be maintained during cash management operations [4][5]. Group 4: Impact on Company - The cash management initiative will not affect the construction of fundraising projects or the normal operation of the company's main business, ensuring the protection of shareholder interests [6].

Core Points - The company has approved the use of idle raised funds for cash management to enhance fund efficiency and returns for shareholders [2][11] - The total amount allocated for cash management is 382 million yuan [3] - The source of funds is from the company's initial public offering, which raised a net amount of 1.03357 billion yuan after deducting issuance costs [5][6] Cash Management Overview - The purpose of cash management is to utilize idle funds without affecting project construction and normal operations [2] - The cash management products are structured deposits with a focus on capital preservation and low risk [10] - The company has established a dedicated settlement account for cash management products to ensure compliance with regulations [1] Investment Details - The cash management investment will not exceed 450 million yuan and is valid for 12 months [11] - The company has a structured approach to managing and utilizing raised funds, adhering to regulatory guidelines [7] - The company has implemented measures to monitor and control investment risks associated with cash management [12][13] Impact on the Company - The use of idle funds for cash management is designed to improve efficiency and generate returns without compromising ongoing projects [14] - The financial results from cash management will be reflected in the company's financial statements as per accounting standards [14] - The company aims to ensure that this strategy does not harm the interests of shareholders, particularly minority shareholders [14]

关于使用部分闲置募集资金进行现金管理到期赎回及注销 理财产品专用结算账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、使用部分闲置募集资金进行现金管理的审议情况 赛力斯集团股份有限公司（以下简称"公司"）于 2024 年 8 月 23 日分别召开第五 届董事会第十五次会议、第五届监事会第十二次会议，审议通过了《关于使用部分闲置 募集资金进行现金管理的议案》，同意公司使用不超过人民币 20 亿元的暂时闲置募集 资金进行现金管理，在上述额度内，资金可循环使用，使用期限自董事会审议通过之日 起 12 个月内有效。具体内容详见公司于 2024 年 8 月 26 日披露的《关于使用部分闲置 募集资金进行现金管理的公告》（公告编号：2024-081）。 二、使用部分闲置募集资金进行现金管理到期赎回的情况 截至本公告披露日，公司使用部分闲置募集资金购买的理财产品已全部赎回，具体 情况如下： 证券代码：601127 证券简称：赛力斯 公告编号：2025-064 | | | | 单位：万元 | | | --- | --- | -- ...

Core Viewpoint - The company has approved the use of idle raised funds (including oversubscribed funds) for cash management, with a limit of up to RMB 400 million, to enhance fund utilization efficiency and generate returns for shareholders [1][6][7]. Fundraising Basic Situation - The company raised a total of RMB 51,287.52 million through the public offering of 19 million shares at RMB 46.33 per share, with the funds managed in a dedicated account [1][2]. Reasons for Idle Funds - Due to the construction cycle of fundraising projects, there will be a temporary idle situation of funds. The company plans to utilize these idle funds for cash management without affecting project progress or normal operations [2][3]. Cash Management Details - The purpose of using idle funds is to improve fund efficiency while ensuring project progress and fund safety. The company will invest in low-risk, high-liquidity products [3][4]. - The investment limit is set at RMB 400 million, with a rolling usage period of 12 months from the board's approval date [4]. Decision-Making and Implementation - The management is authorized to make investment decisions and sign contracts within the approved limit and timeframe, with the finance department responsible for implementation [4][6]. Disclosure of Information - The company will comply with relevant regulations for timely information disclosure regarding the use of idle funds [5][6]. Impact on Operations - The cash management will not interfere with the fundraising projects or normal operations, and it aims to enhance fund efficiency and returns for shareholders [6][7]. Review Procedures and Opinions - Both the board and the supervisory committee have approved the cash management proposal, confirming that it aligns with the interests of the company and shareholders [7][9].

国信证券股份有限公司 关于东莞市凯格精机股份有限公司 使用闲置募集资金（含超募资金）进行现金管理的核查意见 国信证券股份有限公司（以下简称"国信证券"、"保荐人"）作为东莞市凯 格精机股份有限公司（以下简称"凯格精机"、"公司"）首次公开发行股票并在 创业板上市的保荐人，根据《上市公司募集资金监管规则》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》等相关规定，对凯格精机使用闲置募集资金（含超募资金） 进行现金管理的事项进行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会证监许可〔2022〕796 号文核准，并经深圳证券 交易所同意，公司向社会公众公开发行人民币普通股（A 股）1,900 万股，每股 面值为人民币 1.00 元，发行价为人民币 46.33 元/股，共计募集资金人民币 对公司首次公开发行股票的资金到位情况进行了审验，并出具了 XYZH/2022GZAA30194 号《验资报告》。公司对募集资金的存放和使用进行专户 管理，并与专户开设银行、保荐人签订了《募集资金三方监管协议》。 （一）投资目的 二、募集资金使用 ...

Core Viewpoint - The company, Ruida New Materials, announced the approval of a proposal to use temporarily idle raised funds for cash management, with a limit of up to RMB 1.3 billion [1] Group 1 - The second meeting of the company's second board was held on August 21, 2025, where the cash management proposal was reviewed and approved [1] - The company will ensure that the use of these funds does not affect the construction of investment projects and will effectively control risks [1] - The funds can be used for a rolling period of 12 months from the date of approval by the shareholders' meeting, with any single investment amount not exceeding the approved limit [1]

Summary of Key Points Core Viewpoint - The company, Shanghai Aopumai Biotechnology Co., Ltd., plans to utilize part of its idle raised funds for cash management, with a maximum investment amount of RMB 700 million, ensuring high safety and liquidity in the investment products chosen [1][2][8]. Investment Overview - **Investment Purpose**: The aim is to maximize shareholder value by improving the efficiency of fund usage while ensuring that the use of raised funds is not affected and risks are effectively controlled [2][6]. - **Investment Amount and Duration**: The company intends to use up to RMB 700 million for cash management, with the funds being able to roll over within a 12-month period [2][5]. - **Source of Funds**: The funds are sourced from the proceeds of the company's initial public offering, which raised a total of approximately RMB 1.64 billion after deducting issuance costs [2][5]. Investment Methodology - The company will invest in high-safety, liquid financial products such as agreement deposits, structured deposits, time deposits, notice deposits, large certificates of deposit, and income certificates [1][5][6]. - The cash management products will not be used for pledging or for investment purposes in securities [5][6]. Approval Process - The board of directors and the supervisory board approved the cash management proposal during meetings held on August 21, 2025, with a validity period of 12 months from the date of approval [2][6][8]. - The management team has been authorized to make investment decisions and sign relevant contracts, with the finance department responsible for implementation [1][6]. Opinions from Supervisory Board and Sponsor - The supervisory board supports the cash management initiative, stating it will not affect the use of raised funds or harm the interests of the company and its shareholders [7][8]. - The sponsor, Guotai Junan Securities, has confirmed that the cash management plan complies with relevant regulations and will enhance fund usage efficiency without altering the intended use of raised funds [8].

中信证券股份有限公司 关于广东丸美生物技术股份有限公司 使用部分闲置募集资金进行现金管理的核查意见 中信证券股份有限公司（以下简称"中信证券"）作为广东丸美生物技术股 份有限公司（以下简称"丸美生物"或"公司"）首次公开发行股票的保荐人， 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司章程指引》 《证券发行上市保荐业务管理办法》 《上市公司募集资金监管规则》 《上海证券交 易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运 作》等有关规定，对丸美生物使用部分闲置募集资金进行现金管理事项进行了审 慎核查，核查情况及核查意见如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准广东丸美生物技术股份有限公司首次 公开发行股票的批复》 （证监许可[2019]917 号）核准，并经上海证券交易所同意， 丸美生物首次公开发行人民币普通股（A 股）股票 4,100 万股，发行价格为每股 人民币 20.54 元。共计募集资金人民币 84,214.00 万元，扣除各项发行费用人民 币 5,213.80 万元后的募集资金净额为人民币 79,000.20 万元。上述募集资金到位 情 ...